Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-PROT-144

ABSTRACT: Identification of carcinogenesis and tumor progression processes in pancreatic ductal adenocarcinoma using high-throughput proteomics

DISEASE(S): Normal,Pancreatic Ductal Adenocarcinoma

PROVIDER: E-PROT-144 | ExpressionAtlas | 2024-06-05

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-PROT-144-MappedToGeneID.txt	Txt
	E-PROT-144-analysis-methods.tsv	Tabular
	E-PROT-144-configuration.xml	Xml
	E-PROT-144-factors.xml	Xml
	E-PROT-144-pipeline.pdf	Pdf

Items per page:

1 - 5 of 11

Similar Datasets

Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma

Project description:Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma

2023-09-02 | PXD045063 |

Temporally-resolved proteomic profiling of mouse pancreatic cancer

Project description:Pancreatic ductal adenocarcinoma (PDAC) is characterized by progressive matrix deposition and fibrosis, which can enhance tumor progression and spread. Here, we undertook an unbiased temporal assessment of the matrix proteome (matrisome) of the highly-metastatic KPC and poorly-metastatic KPflC mouse models of pancreatic cancer using data independent acquisition (DIA) mass spectrometry proteomics.

2024-08-10 | PXD045830 | Pride

mouse subcutaneous white adipose tissue.

Project description:MThe methionine reactivity in subcutaneous white adipose tissue (sWAT) samples from the non-tumor or tumor mice was unbiasedly analyzed using oxaziridine chemical tool. It provides which proteinaceous methinoines in sWAT could regulated under the progression of cachexia by pancreatic ductal adenocarcinoma (PDAC).

2026-05-29 | PXD063328 | Pride

Expression data from WT mice and bitransgenic Pdx1-cre/Kras*A mice bearing Pancreatic Ductal Adenocarcinoma

Project description:We have carried out transcriptional profile analysis in WT MICE and bitransgenic Pdx1-cre/Kras*A MICE baring Pancreatic Ductal Adenocarcinoma Mouse models faithfully simulating human cancer are valuable for genetic identification of potential drug-targets but, among them, the most advantageous for practical use in subsequent preclinical testing of candidate therapeutic regimes are those exhibiting rapid tumor development. Considering that a KRAS mutation (predominantly in codon 12, such as KRASG12D; KRAS*) occurs with high frequency (~90%) in cases of human pancreatic ductal adenocarcinoma (PDA)1, we sought to develop a mouse PDA model that would exhibit high tumor incidence and short latency by ectopic overexpression of Kras*. Five WT mice and 6 bitransgenic Pdx1-cre/Kras*A MICE baring Pancreatic Ductal Adenocarcinoma were used to identify key genes in the formation of panceatic malignacies

2014-09-01 | E-GEOD-53659 | biostudies-arrayexpress

Tyrosine phosphoproteomics of patient-derived xenografts reveals ephrin type-B receptor 4 tyrosine kinase as novel therapeutic target in pancreatic cancer

Project description:Pancreatic ductal adenocarcinoma is a recalcitrant tumor with minimal response to conventional chemotherapeutic approaches. Oncogenic signaling by activated tyrosine kinases has been implicated in cancers resulting in activation of diverse effector signaling pathways. Thus, discovery of aberrantly activated tyrosine kinases is of great interest in developing novel therapeutic strategies in treatment and management of pancreatic cancer. Patient-derived tumor xenografts (PDXs) in immunodeficient mice serve as potentially valuable preclinical model as it maintain the histological and molecular heterogeneity of the progenitor human tumor. Here, we employed high resolution mass spectrometry combined with immuno-affinity purification using anti-phosphotyrosine antibodies to profile tyrosine phosphoproteome across 13 pancreatic ductal adenocarcinoma PDX models. This analysis resulted in identification of 1,219 tyrosine phosphorylated sites mapping on 724 proteins. The mass spectrometric analysis revealed widespread and heterogeneous activation of both receptor and non-receptor tyrosine kinases. Studies carried out in mice confirmed ephrin type-B receptor 4 (EphB4) as a potential therapeutic target based on the efficacy of human serum albumin-conjugated soluble EphB4 in mice bearing orthotopic xenografts. In summary, we present the comprehensive landscape of tyrosine phosphoproteome with EphB4 as a promising therapeutic target in pancreatic ductal adenocarcinoma.

2021-05-24 | PXD021729 | Pride

Identification of miR-29a-mediated target transcriptome in human pancreatic stellate cells (hPSCs) using RNAseq approach

Project description:In this study, we aim to understand the role of miR-29a in in regulating hPSCs. Identification of the differentially expressed direct and indirect miR-29a targets and the associated pathways from the RNASeq data delineates gene interactions and networks essential for activated PSCs in pancreatic ductal adenocarcinoma (PDAC) in regulating desmoplasia and tumor-stomal crosstalk, which are crucial mechanisms for PDAC progression.

2020-07-20 | GSE144767 | GEO

LLGL1 depletion effect on pancreatic ductal adenocarcinoma cell line CAPAN2

Project description:Identification of gene regulated by LLGL1 in pancreatic ductal adenocarcinoma cell line CAPAN2

2015-01-06 | GSE64681 | GEO

Identification of malignant phenotype related genes in pancreatic ductal adenocarcinoma

Project description:To explore malignant phenotype related genes in Panc-1-CTC, we performed gene expression array analysis with Panc-1-CTC and Panc-1-Parent (Panc-1-P). As a result, TGFBI upregulation emerged as highly malignant feature for pancreatic ductal adenocarcinoma. Identification of malignant phenotype related genes in pancreatic ductal adenocarcinoma

2018-08-24 | GSE118556 | GEO

Development of lncRNA and Mrna expression signatures for pancreatic ductal adenocarcinoma

Project description:To further development of our lncRNA and mRNA expression approach to pancreatic ductal adenocarcinoma(PDAC), we have employed lncRNA and mRNA microarray expression profiling as a discovery platform to identify lncRNA and mRNA expression in pancreatic ductal adenocarcinoma.Human pancreatic ductal adenocarcinoma tissues and normal pancreatic tissues from PDAC donors and other duodenum diseases donors. analyze mRNA and lncRNA expression in pancreatic ductal adenocarcinoma (PDAC) by microarray platform

2014-11-18 | E-GEOD-57144 | biostudies-arrayexpress

Induced Pluripotent Stem Cells From Pancreatic Ductal Adenocarcinoma Can Recapitulate Early Developmental Stages of Cancer

Project description:Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses of any human malignancy and there are few human cellular models of disease progression. When human PDAC cells are injected into immunodeficient animals, they create tumors of the late stage from which they were derived. We hypothesized that if human pancreatic cancer cells were converted to pluripotency and then allowed to differentiate back into pancreas, the developmental progression would recapitulate early stages of the cancer. To that end, we have generated isogenic matched sets of induced pluripotent stem (iPS) cell-like lines from epithelial cells of human pancreatic tumors and from histologically normal epithelial cells at the resected pancreatic margins. Notably, when injected into immunodeficient mice, at low or high passages, a human pancreatic cancer iPS-like line, but not the corresponding margin iPS-like line, slowly generates intra-epithelial neoplasia (PanIN) ductal structures that typically reflect the early stages of human pancreatic cancer. The PanIN-like ducts can be isolated and cultured. They secrete protein products reflective of PanINs and provide new insights into underlying regulatory networks. An additional iPS-like line from histologically normal cells at a pancreatic resection margin, but containing a mutation that predisposes to PDAC, does not generate PanIN ductal structures. These studies demonstrate that iPS technology can be exploited to recapitulate early progression events of a human epithelial cancer. Study includes a single experiment (#10): a tumor-adjacent pancreatic tissue control (10N); tumor tissue (10C); IPS-transformed tissue control (10N12); and IPS-transformed tumor tissue (10C22).

2013-06-20 | E-GEOD-47985 | biostudies-arrayexpress